Edwards Lifesciences - 股票

Edwards Lifesciences 市值 2024

Edwards Lifesciences 市值

54.14 亿 USD

股票代码

EW

ISIN

US28176E1082

WKN

936853

在2024年,Edwards Lifesciences的市值为54.14 亿 USD,比前一年的市值55.33 亿 USD增长了-2.15%

Edwards Lifesciences 市值 历史

营业额 (undefined USD)毛利率 (%)利润 (undefined USD)
2029e10.5543,842.89
2028e9.6348,012.64
2027e8.8852,112.42
2026e8.1157,002.15
2025e7.4262,331.94
2024e6.7668,431.72
2023677,021.4
20225.3879,931.52
20215.2376,131.5
20204.3975,360.82
20194.3574,371.05
20183.7274,770.72
20173.4474,520.58
20162.9673,090.57
20152.4975,250.49
20142.3273,070.81
20132.0574,740.39
20121.974,150.29
20111.6870,820.24
20101.4571,780.22
20091.3269,800.23
20081.2466,100.13
20071.0965,340.11
20061.0463,970.13
2005162,460.08
20040.9360,260

Edwards Lifesciences Aktienanalyse

Edwards Lifesciences在做什么?

Edwards Lifesciences Corp is a globally operating company in the field of medical technology, specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. The company was founded in California in 1958 and is now one of the leading companies in the field of modern heart valve technology. The history of Edwards Lifesciences begins with its founding by Miles "Lowell" Edwards and his longtime employee Dr. Albert Starr. They recognized the need for a less invasive and more effective alternative to heart valves than the existing surgical methods. They received their first patent in 1960 and performed their first successful heart valve operation on a sheep in the same year. The first surgeries on humans took place in 1962. Edwards Lifesciences quickly expanded in the US and internationally. The business model of Edwards Lifesciences focuses on three business areas: "Transcatheter Heart Valve Systems," "Surgical Heart Valve Therapy," and "Critical Care." Each area is focused on a specific range of products and is supported by its own team of professionals. The "Transcatheter Heart Valve Systems" area has become the most important division of Edwards Lifesciences. This novel technology enables the implantation of an artificial heart valve system through minimally invasive surgical methods, without the need for an open procedure. The system consists of a foldable heart valve made of animal tissue or artificial material, which is inserted into the damaged heart through a catheter. This method is applicable to a wide range of patients and has become an important tool in the treatment of heart diseases. The "Surgical Heart Valve Therapy" business area includes implantable mechanical and biological heart valves for open surgical procedures. Edwards Lifesciences develops innovative products to meet the needs of surgical patients and doctors. The third business area, "Critical Care," offers instruments and technologies for the critical medical care of patients in intensive care units and emergency departments. The company manufactures collagen matrix products for wound care, catheter monitoring systems, and patient monitoring devices to detect potential life-threatening complications early. Over the years, Edwards Lifesciences has introduced numerous innovative products to the market that are used in medical practice. The Edwards SAPIEN Transcatheter Heart Valve System was approved in Europe in 2011 and in the US in 2012 and has since improved the lives of tens of thousands of patients. With new technologies such as the Edwards SAPIEN 3 and SAPIEN 3 Ultra platforms, the company is constantly striving to increase the effectiveness and safety of heart disease treatment. Edwards Lifesciences is headquartered in Irvine, California, and is a multinational company with locations in North America, Europe, India, and Asia. The company currently employs approximately 14,000 people worldwide and is an important pillar of the medical community. Answer: Edwards Lifesciences Corp is a global medical technology company specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. It is a leader in modern heart valve technology. Edwards Lifesciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

市值的详细信息

Edwards Lifesciences的市值分析

Edwards Lifesciences的市值代表了公司在美元中的所有未流通股票的总市场价值。它是通过将公司的未流通股票数乘以每股的当前市场价格来计算的。这个指标是一个关于公司规模,实力和整体市场价值的重要指标。

年度对比

Edwards Lifesciences市值的年度对比能为投资者和分析师提供公司的增长和估值趋势的观察视角。一次增加可能表明市场信任和业务扩展,而一次减少可能表明市场价值下降或业务衰退。

对投资的影响

Edwards Lifesciences的市值在投资决策中发挥了重要的作用。它帮助投资者评估公司的风险以及收益水平。大公司通常被视为更稳定,但可能提供较低的增长潜力,而小公司可能提供明显的增长前景,但可能风险较高。

市值波动的解读

Edwards Lifesciences的市值波动可能由多种因素引起,包括股票价格的变动、未流通股票数的变化以及市场情绪的变化。了解这些波动有助于投资者评估公司在竞争环境中的当前位置和未来潜力。

关于Edwards Lifesciences股票的常见问题

Edwards Lifesciences的市值目前是多少?

Edwards Lifesciences的当前市值为54.14 亿 USD。

什么是市值?

市值(英语:market capitalisation,简称market cap,也叫做股票市场总值或股票总价值)是所有已在股票市场上市的公司如Edwards Lifesciences的股票总值。

Edwards Lifesciences的市值在过去几年里发展如何?

与去年相比,Edwards Lifesciences的市值增长了-2.15% 下降。

市值对投资者意味着什么?

一个公司的市值反映了市场对上市公司股权价值的当前共识。

为什么市值是投资者的重要指标?

一家公司的市值反映了市场对上市公司股权价值的当前共识。它由公司股票的供需决定。因此,市值在很大程度上受到股市对公司未来盈利能力的期望影响,可能会出现强烈波动。

为什么市值会波动?

市值会随着股价的波动而波动,因为市值是由当前价格和流通股数量计算得出的。

Edwards Lifesciences的评估中市值起着什么样的作用?

为了能够比较企业的价值,除了市值之外,了解企业的净债务也是有帮助的。如果有人要购买整个企业,那么在购买时也会同时购买企业的债务。企业价值或者说企业价值是企业或股份有限公司的总价值。企业的净负债会计入其市值。

Edwards Lifesciences的市值是否影响其表现?

没有任何可证实的长期证据或研究表明,具有特定市值(无论是超大盘/大盘/中盘/小盘)的股票会长期产生明显高于其他股票的收益。偶尔会有一些小型研究(股票少,投资期短),表明某些类别的表现更好或风险更高,但没有任何研究1.具有决定性的(因果关系不清楚,实验不可重复)或2.普遍适用(不能概括,因为样本和时间段太小)。

Edwards Lifesciences的市值是否影响指数?

一些股票指数使用市值作为指数权重。市值较高的股票在指数中的权重也会较高。这与等权重指数(所有股票有相同的权重)和流通股权重指数(市值权重,但只计算流通在外的股票数量)相对立。

Edwards Lifesciences支付多少股息?

在过去的12个月中,Edwards Lifesciences支付了 的股息。这相当于大约的股息收益率。在未来的12个月内,Edwards Lifesciences预计将支付0 USD的股息。

Edwards Lifesciences的股息收益率有多高?

Edwards Lifesciences当前的股息收益率为。

Edwards Lifesciences什么时候支付股息?

Edwards Lifesciences按季度支付股息。这些股息将在月份分发。

Edwards Lifesciences的股息有多安全?

Edwards Lifesciences 在过去0年里每年都支付了股息。

Edwards Lifesciences的股息有多高?

预计未来12个月的股息将达到0 USD。这相当于0 %的股息收益率。

Edwards Lifesciences位于哪个行业?

Edwards Lifesciences 被分配到“健康”板块。

Wann musste ich die Aktien von Edwards Lifesciences kaufen, um die vorherige Dividende zu erhalten?

要获得Edwards Lifesciences在支付的0 USD的最后一笔股息,你必须在的除息日之前持有该股票于你的账户中。

Edwards Lifesciences最后一次支付股息是什么时候?

上一次股息发放日期为。

Edwards Lifesciences在2023年的股息是多少?

在2023年,Edwards Lifesciences 分配了0 USD作为股息。

Edwards Lifesciences 的股息是以哪种货币支付的?

Edwards Lifesciences的股息将以USD的形式分配。

股票储蓄计划为投资者提供了一种吸引人的方法,可以长期累积财富。主要优势之一是所谓的成本平均效应:通过定期投入固定金额于股票或股票基金,当价格低时自动买入更多份额,价格高时买入较少,这可能随着时间带来更优惠的平均每份成本。此外,股票储蓄计划还允许小额投资者接触到高价股票,因为他们可以用很小的金额参与其中。定期投资也促进了一种纪律投资策略,并有助于避免情绪化的决策,如冲动买卖。除此之外,投资者还能从股票的潜在增值以及可以再投资的股息分红中获益,这增强了复利效应,从而增加了投资资本的增长。

Edwards Lifesciences 股票在以下供应商处可进行定投计划:Trade Republic

Andere Kennzahlen von Edwards Lifesciences

我们对Edwards Lifesciences 营业额股票的股票分析包括重要的财务指标,如收入、利润、市盈率、市销率、息税折旧摊销前利润,以及有关股息的信息。此外,我们还研究了诸如股票、市值、债务、股东权益和Edwards Lifesciences 营业额的负债等方面。如果您在寻找关于这些主题的更详细信息,我们在子页面上提供了详细的分析: